ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 110 for:    Recruiting, Not yet recruiting, Available Studies | "Blood Glucose"

Predictive Value Of Admission Blood Glucose Level In Patients With Acute Myocardial Infarction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03164707
Recruitment Status : Not yet recruiting
First Posted : May 24, 2017
Last Update Posted : May 24, 2017
Sponsor:
Information provided by (Responsible Party):
George Motea Ghayes, Assiut University

Brief Summary:

Coronary atherosclerosis is the leading cause of death worldwide. Diabetes mellitus is associated with increased prevalence of coronary artery disease

Increased plasma glucose is a common feature in the acute phase of myocardial infarction, even in patients without diabetes. Patients with stress hyperglycemia, but without previous diagnosis of diabetes, were at increased risk of congestive heart failure, arrhythmia and cardiogenic shock as well as increased both in-hospital and long-term mortality . Previous studies have demonstrated larger infarct size and poorer prognosis inpatients with hyperglycemia upon hospital admission compared with patients without hyperglycemia

It has been reported that stress hyperglycemia impairs microvascular circulation and may lead to no-reflow phenomenon. No reflow phenomenon was significantly more frequent among patients with hyperglycemia and increased progressively with increasing admission blood glucose in patients with Acute Myocardial Infarction . Furthermore, patients with high admission glucose are more likely to develop restenosis and require repeat revascularization procedures compared with those with normal admission glucose and are also at increased risk for repeated Myocardial Infarction, stent thrombosis and death.


Condition or disease Intervention/treatment
Predictive Value of Admission Blood Glucose Level in Acute Myocardial Infarction Diagnostic Test: Blood Glucose Level

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Predictive ValueOf Admission Blood Glucose Level In Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Angioplasty
Estimated Study Start Date : December 1, 2017
Estimated Primary Completion Date : December 1, 2018
Estimated Study Completion Date : June 1, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Dextrose


Intervention Details:
  • Diagnostic Test: Blood Glucose Level
    ON Admission Blood Glucose Level Fasting Blood Glucose Level


Primary Outcome Measures :
  1. Correlation of level of blood glucose on admission in patients with ST Segment Elevation Myocardial Infarction and Hospital Outcome [ Time Frame: 1 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Patients with Acute ST Segment Elevation Myocardial Infarction admitted in Assiut University Hospital
Criteria

Inclusion Criteria:

acute ST Segment Elevation Myocardial Infarction patients not known to have Diabetes Mellitus undergoing primary PCI.

Exclusion Criteria:

  • patients known to have Diabetes mellitus (known diabetes mellitus on admission, which was treated with diet, oral glucose-lowering medication, and/or insulin).
  • Patients with prior Primary Percutaneous Intervention and/or Coronary Artery Bypass Graft (altering disease state).
  • Patients with severe liver or renal disease (altering disease state).
  • Patients with anemia, kidney disease or certain blood disorders (thalassemia).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03164707


Contacts
Contact: Amr Ahmed Yousef, Professor 01006554042 ext +2 Amryoussef111@yahoo.com
Contact: Heba Mahmoud Elnaggar, Lecturer 01001963100 ext +2 Heba_m_elnaggar@yahoo.com

Sponsors and Collaborators
Assiut University
Investigators
Principal Investigator: George Motea Doos, M.B.B.CH Assiut University

Publications of Results:
Responsible Party: George Motea Ghayes, Principal Investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03164707     History of Changes
Other Study ID Numbers: Serum Blood Glucose Level
First Posted: May 24, 2017    Key Record Dates
Last Update Posted: May 24, 2017
Last Verified: May 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
ST Elevation Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases